EBMT-EHA 8th European CAR T-cell Meeting

UPDATE: Late-Breaking Abstract submission period has now closed.

Abstracts & Case Submission

As a participant, you will have the opportunity to submit an abstract and (if accepted) have the possibility to discuss it with the international faculty and your peers. 

Dates

Items

Please note that submitting an abstract constitutes a formal commitment by the author to attend the meeting in Palma de Mallorca, Spain (should the abstract be accepted). If requested, the author must also present the work as an oral or poster presentation during the assigned session and time slot in the scientific programme.

Introduced in 2021, we are excited to announce the 6th Emerging Investigators EBMT-EHA Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy. The Scientific Programme Committee will select three winners. Find more information here.

Oral presenting authors of accepted abstracts or cases will be allowed to register with the Early Bird registration discount fee, for which the details will be shared in the acceptance letter.

All other authors wishing to attend the meeting should complete their registration before 8 18 December 2025 (23:59 CET) to take advantage of the early registration discount fee.

Submission procedure

• The abstracts / clinical cases submitted via the submission portal will be reviewed and allocated by the Scientific Programme Committee (SPC).

Regular abstract/clinical case submission

• Submission duration: 10 July 2025 - 16 23 November 2025 (23:59 CET)
• Authors will be informed about the allocation by 26 November 12 December 2025

Late-breaker abstract/clinical case submission

Groundbreaking, high-impact research with recent, time-sensitive data that could not have been available during the regular submission period. It is not intended for work delayed due to time constraints, but for studies with the potential to significantly influence practice or advance science.

• Submission duration: 1 January 2026 - 11 January 2026 (23:59 CET)
• Authors will be informed about the allocation by 19 January 2026

Should you have any questions regarding the abstract submission or terms, please contact education.events@ebmt.org

Guidelines for the abstract/clinical case submission

The Abstract and Clinical Case Submission Guidelines of the 8th European CAR T-cell Meeting are intended to provide clear instructions before submitting an abstract. You are kindly requested to carefully read the guidelines.

• Text 400 words max
• They can be structured (e.g. Objectives, Methods, Results, Conclusions)
• Images have to be submitted as JPEG, TIF, or GIF file
• Due to limited space, only a simple graph/image can be submitted
• Image file should not exceed 500 KB
• Tables should be created as so
• Mention all the authors
• Disclosures and affiliation of all authors
• Authors: There is no limit to the number of authors
• References are obligatory when submitting an abstract or clinical case

Abstract and clinical case submission topics (regular submission)

• Access to CAR T
• Advanced Practice Roles within the Multidisciplinary team in CAR T Therapy
• CAR-based Cellular Therapy — Clinical: Biomarkers for CAR T efficacy and prediction model for response and toxicity
• CAR-based Cellular Therapy — Clinical: Challenges of CAR-based cellular therapy (bridging therapies and lymphodepletion), and clinical indication
• CAR-based Cellular Therapy — Clinical: Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/paediatric indications
• CAR-based Cellular Therapy — Clinical: Management of toxicities (early and late)
• CAR-based Cellular Therapy — Preclinical: CAR T cell manufacturing methodologies
• CAR-based Cellular Therapy — Preclinical: Innovative T cell engineering, CAR designs and optimization of CAR T cell function
• CAR-based Cellular Therapy — Preclinical: Mechanistic studies of CAR T efficacy and toxicities and tumour resistance
• CAR-based Cellular Therapy — Preclinical: Novel in vivo and in vitro models to functionally evaluate CAR T cells
• Clinical case on multiple myeloma
• Clinical case on new technologies for CAR T development
• Clinical case on solid tumours
• Models of Care and Multidisciplinary Collaboration in CAR T Programmes
• Perspectives in Adolescent and Young Adult (AYA) CAR T Care
• Quality of Life
• Real-world Nursing Practice in CAR T-cell Therapy
• Symptom Management and Toxicity Monitoring in CAR T Patients

Abstract and clinical case submission topics (late-breaker submission)

• CAR-based Cellular Therapy — Clinical: Biomarkers for CAR T efficacy and prediction model for response and toxicity
• CAR-based Cellular Therapy — Clinical: Challenges of CAR-based cellular therapy (bridging therapies and lymphodepletion), and clinical indication
• CAR-based Cellular Therapy — Clinical: Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/paediatric indications
• CAR-based Cellular Therapy — Clinical: Management of toxicities (early and late)